ArticleBMC pulmonary medicine2016

Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.

Hao-Cheng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.